The US approves Pfizer booster dose for at-risk groups
Leading experts were divided over whether a third COVID-19 vaccine should be approved for the entire population.
The U.S. Food and Drug Administration (FDA) has authorized the administration of the third dose of Pfizer / BioNTech coronavirus vaccine to at-risk Americans. This was reported on September 23 by Reuters.
According to the newspaper, people aged 65 and over, people most susceptible to serious illnesses, and those who perform risky work can receive a booster dose at least six months after the second injection.
At the same time, leading FDA experts were divided about whether the third COVID-19 vaccine should be approved for the entire population.
As indicated, the US Centers for Disease Control and Prevention (CDC) Advisory Group may vote today to use the third vaccine. However, experts admit that there is insufficient evidence to support revaccination for all Americans age 16 and older.
As a result, the team requested additional safety data.
Recall that Israel in July was the first in the world to approve the third COVID vaccination for residents of the country aged 60 and over.
TAGS: USA, COVID-19, CORONAVIRUS